C3: Collaborating to Conquer Cancer

C O L L A B O R AT I N G

T O

C O N Q U E R

C A N C E R

W I N T E R 2 011

Serendipity 12: Don’t Call Him Superman

16: Screening Warriors

by de sign

10: Q&A with

Jonathan Gutman, MD

11: C3 MD Lia Gore

18: Supporter Focus on Gary Reece

ANSCHUTZ MEDICAL CAMPUS

target mutations for therapy A University of Colorado Cancer Center team, led by director Dan Theodorescu, MD, PhD, is the first

C o lo rad o te st h e lp s b o o s t s u r v i va l r at e s f o r l u n g c a n c e r p at i e n t s

to sequence the most prevalent type of bladder cancer.

The gene sequencing project, done in partnership with universities in China and Denmark, allows

Get more CU Cancer Center news on our blog: www.coloradocancerblogs.org

Read the stories here in full and sign up for our bimonthly email, Colorado Cancer News.

205

f e w e r wo m e n screened

In 2003, CU Cancer Center

Common class of pain drugs reduces severity of postpartum breast cancers The ibuprofen found in most household medicine cabinets could prove to be an effective treatment for postpartum breast cancers if animal model research,

researchers to recognize genetic mutations that make bladder cancer cells different from their healthy

investigators Fred Hirsch, MD,

neighbors. That information may allow early genetic screenings for bladder cancer and new therapies

PhD, and Wilbur Franklin, MD,

published in August in Nature Medicine

for cells with these mutations.

created a test that identifies

by Colorado cancer researchers, holds

“When we talk about ‘causes’ of cancer, there’s a black box between a healthy cell and the emergence of cancerous ones,” Theodorescu says. “By exploring the genetic changes that take place inside this box, we can look at the links of the chain of events that lead to cancer and, hopefully speaking, target About 69,250 people in the United States are predicted to be diagnosed with bladder cancer this year,

true in humans.

key biomarkers in advanced Fewer women getting mammograms

lung cancer.

after 2009 guideline revision

Now, a European clinical trial shows that patients identified with

specific links for therapy.”

this test as having high levels of

Hi rsch

Pepper Schedin, PhD, and Virginia Borges, MD, MMSc, co-directors of

A 2009 recommendation to stop screening

the University of Colorado Cancer

women between the ages of 40 and 49 for

Center Young Women’s Breast Cancer

and 14,990 will die, according to the National Cancer Institute. It’s the fourth most common type of cancer

the biomarker, called epidermal growth factor

breast cancer using mammograms has begun

Translational Program, have been work-

in men and ninth most common type in women. Smoking is a leading cause of the disease.

receptor, have 36 percent better survival rates

to negatively affect the number of yearly

ing on the hypothesis that the process

when treated with the drug cetuximab and chemo-

mammograms performed in this age group.

responsible for killing milk-producing

therapy. Cetuximab, or Erbitux, is primarily used to

The recommendation from the United States

cells in the breast after pregnancy, called

fight colorectal and head and neck cancers.

Preventive Services Task Force may also

involution, contributes to a 30 percent

interfere with the possibility of the early

increase in breast cancer in women who

detection of breast cancer.

have children after age 35. Postpartum

The study was reported online in the Aug. 7, 2011 issue of Nature Genetics.

UCH, Children’s among nation’s best for cancer care The University of Colorado Cancer Center’s lead cancer care partners have been ranked among the top hospitals for cancer care in the 2011-2012 U.S. News & World Report Best Hospitals and Best Children’s Hospitals surveys. University of Colorado Hospital was ranked 34th for adult cancer care and Children’s Hospital Colorado was ranked 10th for pediatric cancer care among hospitals nationwide. Both hospitals are part of the CU Cancer Center consortium, a National Cancer Institute-designated comprehensive cancer center. Both hospitals are the top-ranked cancer care facilities in Colorado.

University of Colorado Hospital was also ranked as the top-performing academic hospital in the United States for delivery of quality heath care by University HealthSystem Consortium, the 114-member

“With this personalized medicine we can identify subgroups of patients that can get better effects from certain drugs,” Hirsch says. “In some

Colorado cancer researchers share $9.55 million grant to learn how

University of Colorado Hospital performed

sive, with increased risk of spreading

screening mammograms for 205 fewer women

to other organs, and have much lower

percent at best. This is a huge improvement but

in the 40-49 age range than in the previous

five-year survival rates.

everything is based on the selection criteria.”

year, according to a study by CU Cancer

About 30 percent of people with non-small cell lung cancer have elevated levels of EGFR.

lyn n clark

have access to the nation’s first cancer stem cell

director Dan Theodorescu, MD, PhD,

clinical trial, aimed at giving the cells a “one-two

and center investigators Scott Lucia, MD,

punch” of drugs, according to CU Cancer Center

and Jeff Kieft, PhD, have been awarded

investigator Antonio Jimeno, MD, PhD. While cancer stem cells may form roughly

Sche din, Borge s

Center investigator Lara Hardesty, MD, chief

Traci Lyons and Jenean O’Brien, discovered

of breast imaging at University of Colorado

that breast involution increases production of an

“We caution patients and providers that

Hospital and associate professor of radiology

enzyme called COX-2, which non-steroidal anti-

because a mother’s body is undergoing radical

at the CU medical school.

inflammatory drugs (NSAIDs) like ibuprofen and its

changes during this time, we can’t yet speak to the

more targeted cousin, celecoxib, inhibit.

safety of these drugs for women diagnosed with or

In a separate study, Hardesty also found

The team tested the treatment in postpartum

referring physicians are beginning to follow the

at risk for postpartum breast cancer, and thus can’t

revised recommendations. Hardesty says,

mice with breast cancer, and found that ibuprofen

yet recommend NSAIDs as a preventative therapy

“If the trend continues, we may miss the oppor-

and celecoxib treatment reduced mammary tumor

or cancer treatment,” cautions Schedin, professor

tunity to diagnose breast cancer in its early

size, collagen architecture, COX-2 expression and

of medical oncology at the CU medical school.

stages, and early detection is crucial.”

breast tumor cells spreading into the lung.

Two CU Cancer Center scientists

especially resistant to traditional chemotherapies

to detect ovarian cancer recurrence

lauded as Boettcher Investigators

and many researchers believe they contribute to

CU Cancer Center investigators Lynne Bemis, PhD, and Monique Spillman,

CU Cancer Center investigators Robert Doebele,

relapse by repopulating a tumor post-therapy.

MD, PhD, have received a grant from the HERA Women’s Cancer Foundation

MD, PhD, who studies drug resistance in

to design a test that returns quick, accurate results about whether ovarian

oncogene-driven lung cancer, and Jing Wang, PhD, who studies antibody production and genomic

1 to 2 percent of a tumor’s mass, they are

as prostate cancer progresses to a therapy-resistant state. the National Cancer Institute grant

The team, which includes trainees

Bemis, Spillman aim to develop accurate, easy test

the molecular changes that occur

The Colorado researchers share

The phase I clinical trial is based on preclinical

with a multidisciplinary team from

animal studies that Jimeno calls “striking.”

cancer has returned. Bemis, a basic researcher and associate professor of

University of Virginia, led by Bryce M.

It combines the drug cetuximab with the anti-

medical oncology at the CU medical school, and Spillman, a gynecological

Paschal, PhD.

cancer-stem-cell agent IPI-926, developed by

oncologist, surgeon and assistant professor of obstetrics and gynecology

When caught in its early stages,

Infinity Pharmaceuticals. The first agent targets

at the CU medical school, will develop a urine-based test that looks for

prostate cancer is treatable in most

the tumor’s mass and the second disrupts the

small molecules called microRNAs that are either over- or under-expressed

cases. But once it reaches a critical

“hedgehog” signaling pathway that tells cancer

as an indicator of recurrence. The pair aim to define the “signature” for the

second year, supports early-career scientists in

threshold, the disease transforms to

stem cells to regenerate killed cancer tissues.

microRNAs that are the most predictive of ovarian cancer, and then to

their work toward making discoveries that improve

develop a test that could be administered in any doctor’s office.

human health. Last year, CU Cancer Center

become largely resistant to current

Luci a, Ki eft, Th eodor e sc u

F i r st can c e r ste m c e ll c li n i cal tr ial o p e n s at CU C a n c e r C e n t e r

University of Colorado Cancer Center

a $9.55 million, five-year grant to define

breast cancers tend to be more aggres-

the cure rate for advanced lung cancer is 2 to 3

Head and neck cancer patients in Colorado

prostate cancer resists treatment

Since the November 2009 recommendation,

cases there is a potential for a cure. Right now

alliance of the nation’s leading nonprofit academic medical centers. The award is based solely on patient experience data.

gle nn asakawa

CU cancer researchers are first to sequence bladder cancer,

N3WS

The National Institutes of Health grant awards

treatments. These changes include

the project $500,000 over two years, during

alterations in how the cancer cells

which Jimeno, director of the Cancer Stem

respond to signals and what genes

Cell-Directed Clinical Trials Program, hopes to

are expressed, researchers say.

enroll 18 to 24 people with relapsed head and

research project is one step toward the goal of developing a test that detects

neck cancer.

cancer when it is treatable—and still confined to the ovaries.

do ebele

instability in B lymphocytes, have been named to the 2011 Class of Boettcher Investigators in the Webb-Waring Research Program.

The Boettcher Investigators Program, in its

The current test for ovarian cancer recurrence after treatment requires

researcher Paul Jedlicka, MD, PhD, received

a blood draw and can return false positives created by a variety of factors.

the award.

Most ovarian cancer is diagnosed when it is no longer curable. This Wang

2

3 www.coloradocancercenter.org

C3: Winter 2011

ve e r

Serendipity

Listen to Dr. Garcia explain the ALK images.

by Ga rt h S u n d e m

by

In the University of Colorado Cancer Center’s fight against lung cancer, what looks like luck on an ordinary day is the product of forethought, experience, and a willingness to ride the winds of change.

I

de sign

n August 2007, Marileila Varella-Garcia went to Paul Bunn’s office to ask for $10,000.

Research grants take months and Garcia’s intuition told her not to wait—the prestigious scientific journal Nature had just linked a type of lung cancer to a specific genetic mutation, and Garcia, PhD, renowned international expert on cancer cell genetics, wanted to know which patients had it. She needed $10,000 to develop the test.

Bunn is no slouch himself. At a 2010 conference of the American Association for Cancer Research and the International Association for the Study of Lung Cancer, Bunn was honored for his leadership in lung cancer research, with the conference chair calling him an “inspiration to physicians and scientists working in the field of lung cancer.”

Over the years, the handsome, grey-haired Bunn has built a world-class lung cancer treatment and research team at the CU Cancer Center, and was instrumental in bringing Garcia onboard in 1993. And because Paul Bunn holds an endowed chair—the James Dudley Chair in Cancer Research—he doesn’t live grant-to-grant, but instead has his own yearly research endowment to spend as he sees fit. By 2007, Bunn and Garcia had worked together for 14 years, and so when Garcia asked, Bunn trusted Garcia’s hunch and gave her $10,000 from his discretionary research account.

Garcia took it to the lab.

When the inchworm is stretched out, the pattern of its feet forms the blueprints of the body’s proteins. Now imagine this inchworm, inching—bringing its feet up to just behind its head. This is what chromosome No. 2 does in 3 percent of non-small-cell lung cancer patients. Instead of making a healthy ALK protein from the worm’s front half and a healthy EML4 protein from its back half, the bunched worm makes an ALK-fusion protein from the squished-together bits of tip and tail. This ALK-fusion protein causes lung cancer in about 45,000 people each year. Lung cancer in general remains the leading cause of cancer deaths worldwide.

In the world of cancer research $10,000 is a tiny drop in a mighty ocean, but it was this drop, dripped in just the right place, that allowed Garcia to develop a specific test for these ALK-fusion proteins in lung cancer patients.

“It’s a tricky test because the two partners are on the same chromosome and not far apart, and when they fuse they’re on the same gene not so far apart,” Bunn says.

Relying on her experience, her expert research team, and the center’s Cytogenetics Shared Resource, which she directs, by the end of November 2007, Garcia had her test.

image s c ourt e sy of t he garc ia lab

I m ag i n e a c h r o m o s o m e a s a n i n c h wo r m

ALK positive

M e a n w h i l e , lu n g ca n c e r pat i e n t s w e r e f i g ht i n g f o r t h e i r l iv e s Elsewhere at the CU Cancer Center, Ross Camidge, MD, PhD, clinical director of the Thoracic Oncology Program, was chugging away on a drug trial for Pfizer. Patients in the study were tested for a different mutation, one in the MET gene, and the drug Camidge’s patients were taking through the center’s Developmental Therapeutics Clinic was supposed to nix the function of this faulty gene.

The phase I safety trial of this drug was taking place at a number of hospitals around the country, notably also at the juggernaut of Massachusetts General Hospital in Boston, but because the CU Cancer Center was the only site in the west, “We got patients from California, Washington, Las Vegas,” Garcia recalls.

In this large trial, little CU was a close second to Mass General in patient enrollment.

As can be the case with these safety studies, some patients responded while others didn’t, and overall the drug was showing only middling results. The goal isn’t to find out if the drug works, but rather what side effects happen at different dosages or schedules. But then the news of this new cancer-causing gene, ALK, broke in the journal Nature—and Pfizer quickly changed the tune of its clinical trial.

The drug that Camidge and others were testing didn’t just nix the first target, MET, but also nixed the function of this newly described ALK-fusion gene.

Maybe it wasn’t that Pfizer’s drug didn’t work, but rather that they were giving it to the wrong patients? It’s like offering macaroni and cheese to a food critic and a 5-year-old: The same meal makes one salivate and the other cringe. Pfizer decided to see how its drug worked with the patients who salivated, the ones with ALK-fusion genes.

Pfizer asked who among its participating centers could test for this ALK-fusion gene.

ALK positive “split”

ALK negative

This ALK-fusion protein causes lung cancer in about

Ga r c ia ra i s e d h e r ha n d

45,000 people each year. Lung

There were only two places in the country with the ability to test for this gene: Mass General and, due to Garcia and Bunn’s foresight, the CU Cancer Center.

“Because we could do the molecular test here, we became a partner and not an outpost,” Garcia says.

In 2008, Pfizer hired Mass General and the CU Cancer Center to run these genetic tests and enroll ALK-positive patients into a phase I clinical trial of their drug.

“Camidge got patients, he would send their samples to me, and in three days he knew if they were ALK-positive,” says Garcia.

cancer in general remains the leading cause of cancer deaths worldwide.

4

5 www.coloradocancercenter.org

C3: Winter 2011

gle nn asakawa

L i f e a ft e r ha p p i ly e v e r a ft e r

Marileila Varella-Garcia, PhD, with her lab staff.

Because the CU Cancer Center is comparatively nimble, it was able to sprint. The center soon started testing patients with Marileila Varella-Garcia’s molecular spyglass and enrolling them on a refocused trial of Pfizer’s drug.

The results were dramatic.

“You spend all your time planning things and then stuff just happens and you have to run with it,” Camidge says.

Because the CU Cancer Center is comparatively nimble, it was able to sprint.

The center soon started testing patients with Garcia’s molecular spyglass and enrolling them on a refocused trial of Pfizer’s drug. The results were dramatic.

“When one patient shows a benefit, it might be a fluke,” Bunn says. “But when the number gets to ten, you know you have something special.”

O n e o f th e s e pati e nts was E lle n S m it h After being diagnosed with lung cancer in 2008, Smith had undergone a spring and summer of chemotherapy followed by surgery to remove her left lung and then radiation through the fall. Finally, “The doctor came in and the news was spread all over his face,” Smith says. “My lung cancer had spread to five places in my abdominal cavity. He was a great doctor, but basically he said, ‘I don’t know what else I can do for you.’ ” Her doctor was right; there was nothing more he could do. In fact, there was nothing that standard medical science could do.

But Ellen Smith says, “My family and I weren’t ready for that.” Smith has three grown children, five grandchildren and was in a relationship with a man she called her “longtime gentleman friend.” It wasn’t a convenient time to die.

In another serendipitous turn, Smith had retired from her job as a public school teacher and was working as a nanny for a mother who is a thyroid cancer researcher at the CU Cancer Center.

“She said, ‘Ellen, you have to go to the CU Cancer Center.’ She twisted my arm until I went there for a second opinion,” says Smith.

And there at the CU Cancer Center, Ellen Smith stumbled into Camidge, Garcia, Bunn, and a melting pot of scientists and doctors who had spent years preparing for her arrival. She signed a consent form to have her tumor specimen tested, and then she went to Scotland with her gentleman friend to retrace her family roots. It was something she had always wanted to do, and with cancer shutting down her body, it seemed like now or never. She almost didn’t survive the trip. In Scotland, her

Most fairytales end here, but creating remission is only a step on the path to a cure.

“Dr. Camidge told me that a day would come when the ALK inhibitor wouldn’t work,” Ellen Smith says. “That day came about a year and a half later.”

“What do you do when the honeymoon ends, when these people who responded fantastically start to become resistant?” Camidge asks. Cancer is insidious—the same mechanism that allows healthy cells to mutate into cancer cells also helps cancer cells mutate around the barricades of treatments.

First, just as we’ve seen that two lung cancers might not be created equal, so too can pockets of cancer within a patient’s body evolve differences over time. In Ellen Smith, when a follow-up scan showed that just one of her tumor deposits had become resistant to crizotinib, CU Cancer Center radiation oncologist Brian Kavanagh, MD, MPH, was able to blast just this tiny part with stereotactic body radiation. In fact, Kavanagh literally wrote the textbook on stereotactic radiation, which was published in 2004— just another world expert who was fortunately part of Ellen Smith’s treatment team.

“This radiation just deletes one little bit of your body,” Camidge says. “It’s very good for weeding the garden. You don’t throw the baby out with the bath water, just zap the resistant part of the tumor and keep the drug going.”

Eventually all of Ellen’s lung cancer became resistant, and the crizotinib honeymoon was officially over. At that point, most oncologists would’ve been back to the drawing board, guessing at a treatment that could put another barrier in lung cancer’s way.

The CU Cancer Center did better than guess.

Of the 82 ALK-positive patients enrolled in what was supposed to be a trial assessing only the drug’s safety, 90 percent saw their tumors stabilize or shrink, and 57 percent saw their tumors shrink by more than a third.

lynn clark

remaining cancer-blackened lung started bleeding, and she was rushed to the emergency room.

“I was in a foreign country, and I was so frightened,” Smith says. Then, on what she thought was her deathbed in a foreign emergency room, Ellen got a long-distance call from her son. She was a match for the CU Cancer Center clinical trial. Ellen Smith was among the ALK-positive 3 percent. She flew home to Camidge.

By this time Pfizer’s drug had a name—crizotinib—and it ripped Ellen Smith back from the precipice on which she had been standing. Crizotinib works by starving ALK-positive tumor cells of their energy source, and as Ellen’s tumors starved, they shrank by more than 40 percent.

Of the 82 ALK-positive patients enrolled in what was supposed to be a trial assessing only the drug’s safety—a test of the medicine in patients beyond hope who had little to lose if the drug proved unexpectedly dangerous—90 percent saw their tumors stabilize or shrink, and 57 percent saw their tumors shrink by more than a third.

“It was as if their tumors melted away,” Bunn says.

K n ow i n g yo u r pat i e n t s l e a d s to pat t e r n s “One thing that comes from getting to know your patients is learning to listen to them when they tell you about what worked well or what didn’t,” Camidge says. “For example, a 35-year-old man on crizotinib told me he had a new girlfriend, but wasn’t finding her as attractive as he should.” Sure enough when they checked this man, his testosterone was low. In fact, when he checked, 100 percent of Camidge’s male patients on crizotinib developed low testosterone, which, once discovered, was easy to replace.

“We now check testosterone on all our crizotinib patients, and I think this will change the way the drug will safely be given in the future. The only way you get to find out this sort of thing is if you know your patients as people so that they’re comfortable telling you about the intimacies of their lives,” Camidge says. “With a big center, there are more patients, but they may be spread around across multiple doctors and it becomes harder to spot these subtle patterns.”

Because of crizotinib and the CU Cancer Center treatment team that has consistently stayed a step ahead of her cancer, Ellen Smith is walking with her family instead of walking in their memories.

6

7 www.coloradocancercenter.org

C3: Winter 2011

DEC gle nn asakawa lynn clark

Ross Camidge, MD, PhD, clinical director of the Thoracic Oncology Program, was chugging away on a drug trial for Pfizer.

Stayi n g a ste p ah ead But lung cancer never rests, and so CU Cancer Center doctors are already laying the groundwork for Ellen Smith’s next step.

For example, pathologists Wilbur Franklin, MD, and Dara Aisner, MD, whom the CU Cancer Center recently enticed away from the University of Pennsylvania, are growing samples of patients’ tumors in the lab to discover how they evolve around drugs like crizotinib and Alimta. Franklin created the Colorado Molecular Correlates Laboratory, perhaps the nation’s most accomplished facility for testing for genes that drive tumors. In this lab, Franklin grew a large culture of cells from a small sample of Ellen Smith’s tumor. And Aisner developed tests that can tell exactly how these tumor cells develop resistance to drugs.

Still another cook in this crowded kitchen, Robert Doebele, MD, PhD, connects the dots from the tumors of patients like Ellen Smith through Franklin’s cells, using Aisner’s test, to recommendations for the next line of drugs that will hit Smith’s evolving tumor from an angle it hasn’t yet learned to protect, if and when needed.

This flock of therapies developed by a gaggle of scientists and administered by a covey of doctors has kept Ellen Smith alive.

“I’m three years out now,” Ellen Smith says. In that time—that extra time—Ellen married the person she calls her “wonderful gentleman friend.” And then on July 12, 2011, her sixth grandchild was born. “Her name is Lucy and I’m just so completely in love,” Smith says. “I see her twice a week. I go for walks with my daughter and see my granddaughter.”

Because of crizotinib and the CU Cancer Center treatment team that has consistently stayed a step ahead of her cancer, Ellen Smith is walking with her family instead of walking in their memories.

Charles Goodyear invented vulcanized rubber when he spilled a mixture of rubber, sulfur and lead onto a hot stove. Wilson Greatbatch invented the pacemaker when his attempt to monitor heart activity regulated its rhythm. DuPont chemist Roy Pluckett invented Teflon when the gas he was working with cooled into flakes. And on August 26, 2011, vaulting past the usual steps of phase II and III trials, the FDA approved Pfizer’s drug crizotinib, which serendipity in the form of Garcia’s test of Camidge’s patients had plucked from the trash bin of a struggling trial.

Chromosome kink causes cancer, is perhaps also its cure Every cell in your body holds the 20,000-or-so

Unfortunately, in a very special 3-to-5 percent

Like a kindergartner at a state fair, this

genes it needs to do things like grow fingernails

of lung cancers, chromosome No. 2 folds back on

ALK-fusion protein needs to eat sugar in

and solve the New York Times crossword. But

itself, like an inchworm bringing its back feet up

order to function, in this case the sugar-like

not every cell needs to do all these things, and

to just behind its front.

molecule ATP.

so your body turns these genes on and off as needed. For example, your body only needs the

ALK-fusion protein

ATP

gene that makes the protein ALK in the early stages of your developing nervous system. After you form your brain and other nervous goodies, the gene that codes for this ALK protein just sits there silently on inchworm-like chromosome

EML

4

ALK

No. 2, opposite another idle gene called EML4, twiddling its genetic thumbs and thinking deep thoughts about the weather.

EML4

ALK-fusion protein’s mouth—outcompetes, Now instead of exposing the code of its entire

ATP comes along, then the ALK-fusion protein

its head (ALK) and the gene on its tail (EML4).

can’t transmit its signal and the cell doesn’t replicate out of control.

That is, unless the gene is reactivated. age, sunbathe, or let the car door bang closed on your shins while unloading groceries, your

EML

4

ALK

cells die. And so you need new cells. Your body creates them by duplicating old cells. Only, sometimes your body’s copy machine goes awry, allowing mutations to sneak into the genetic

actually—and if its mouth is plugged when

belly, it shows a new code made from the gene on

A LK

When you do unkind things to your body like

But it can’t eat ATP if its mouth is plugged.

Crizotinib competes with ATP for space in the

ALK-fusion protein

AT P

P

Paul Bunn, MD, holds an endowed chair— the James Dudley Chair in Cancer Research.

THE SCIENCE OF CRIZOTINIB

AT

Working with Camidge, new Australian senior fellow Andrew Weickhardt, MD, was the first to pull together the testosterone data from Camidge’s original observation.

Recently Weickhardt submitted the important findings for publication. “Returning a young man’s testosterone to normal is something he is pretty grateful for. It gives them an important piece of their life back,” Weickhardt says.

Spotting another lucky pattern helped Camidge save Ellen Smith’s life a second time.

Because these ALK-positive patients had been treated with crizotinib as a therapy of last resort, they’d commonly tried upwards of five other drugs before starting the crizotinib trial. Camidge noticed that before their cancer had developed resistance, many of these ALK-positive lung cancer patients had done surprisingly well on a drug called Alimta.

“There’s nothing quite like that feeling—like you’re in school and everybody’s doing a math calculation and they all get different answers, but you have this little voice that says maybe they’re all wrong and you’re right and you just stick to your guns,” says Camidge.

He was right about this: If a patient hadn’t seen Alimta before moving down the line to crizotinib, then when lung cancer developed resistance to crizotinib, this Alimta was a spectacular next line of defense. When Ellen Smith’s crizotinib honeymoon ended, as she had never seen Alimta before, Camidge immediately started her on it.

“Confirming the earlier pattern seen with other patients, Ellen had almost as dramatic a response on the Alimta as she did on the crizotinib,” Camidge says. “She’s been on the Alimta for nine months (in Sept. 2011) and I can’t see any sign of active cancer on her scans.”

DINGCANCER

ATP

P AT

codes of these new cells.

Most of these mutations do everything

AL K pro-fusio tei n n

This squished-together code is the blueprint

or nothing—killing the new cell or making no

for an ALK-fusion protein—called a “kinase”—

difference whatsoever. A very few of these

which sends signals telling cells to grow, split,

crizotinib stops ALK-positive lung cancer cold

mutations lead to cancer.

and survive in an out-of-control, cancerous way.

while leaving healthy tissues unharmed. Trials

One of these oncogenic mutations is the

Crizotinib is an ALK inhibitor.

ALK-fusion gene.

The gist is this: by blocking its energy,

at the University of Colorado Cancer Center and elsewhere show that crizotinib halts the growth of 90 percent of ALK-positive, non-small-cell lung cancer patients. —Garth Sundem

But was it serendipity? Louis Pasteur said, “Chance favors the prepared mind,” and in this case, the CU Cancer Center as a whole was that prepared mind. It was ripe for serendipity because Paul Bunn, Marileila Varella-Garcia, Ross Camidge, Andrew Weikhardt, Brian Kavanagh, Dara Aisner, Wilbur Franklin, Robert Doebele and all the other doctors and researchers—small in number but world-class in expertise, creativity and motivation—had built it that way.

“We’re small enough that I could walk down the corridor and knock on Leila’s door and knock on Bob’s door,” says Camidge. And this melting pot of researchers, just big enough to have everything Ellen Smith needed but small enough to remain mixed and nimble, spawned a treatment with the potential to save 45,000 lives a year—that’s two-thirds of the average crowd at a Denver Broncos game.

Imagine sitting in a nearly empty stadium. Now imagine sitting in a full one. That is the difference of the drug crizotinib.

Andrew Weickhardt says, “No one thinks we’re going to pack up our bags and go home tomorrow, but the future seems brighter than it has for a long time in fighting lung cancer.”

Visit www.coloradocancerblogs.org to • Watch a video about this story • Read related news articles • Make a donation to support lung cancer research • Tell your story

8

9 www.coloradocancercenter.org

C3: Winter 2011

Assistant Professor, Medical Oncology, Program for Hematological Malignancies and Stem Cell Transplant, University of Colorado School of Medicine Co-Medical Director, University of Colorado Cord Blood Bank

BY GA RT H S U N D E M

MD L ia G o r e g iv e s k i d s a n d a d u lt s w it h ca n c e r o n e m o r e c ha n c e aga i n st a l l o d d s b y l y nn c l a r k

She used the first year of her Calabresi

patient’s original, leukemic blood as foreign and

Lia Gore’s life has been about

cell transplant team infused a patient at the University of Colorado Cancer Center with

so may not eradicate it entirely. Unless you use a

borrowed time.

stem cells grown from donated umbilical cord blood. In this phase I clinical trial, the

high level of chemotherapy, patients may relapse.

recently pregnant patient was fighting for her life, having delayed treatment for leukemia

Then again, some patients might not be able to

cancer. “Everything I do feels like the bonus round,”

would become the Children’s Experimental

so that her child could develop long enough to live. Here we talk to Dr. Gutman about his

withstand that degree of chemo. It looks as if this

says the pediatric oncologist and head of the

Therapeutics Program. Then she sold the idea to

work and about this fascinating new treatment.

trial with expanded cord blood stem cells may

Children’s Hospital Colorado Experimental

Children’s leadership. “It’s a very expensive enter-

solve both problems—you grow enough to restart

Therapeutics Program.

prise that Children’s supported well,” she says.

funding—and critical protected time away from

Before Gore was born, her mother beat breast

That feeling of extra time, she says, drives her

the clinic—to create a business plan for what

In a few, short years the program would

C3: First, how is your patient?

C3: If it’s the job of stem cells to grow more

the immune system but you also leave a degree

Gutman: She’s doing great. We infused her with

cells, why was it important to grow them in

of mismatch that allows the new blood system to

work in finding the next best treatment for every

become one of the most prestigious phase I

2.7 billion stem cells grown from donated umbilical

the lab first? Why couldn’t you just inject

wipe out traces of the old.

patient she meets. “I love the fact that there are

pediatric clinical trials programs in the country,

cord blood, and instead of the average hospital

these umbilical cord stem cells into the

kids alive today who had the odds against them.

leading the way to allow children with leukemia

discharge at 30 or 40 days after treatment, she was

patient and let them do their thing?

C3: It seems strange that nobody thought

And of all those kids who ultimately didn’t survive,

and brain tumors to participate.

able to go home to her large family and new baby

Gutman: We have in the past—doctors inject

of this before.

a lot of them lived with very high qual-

11 days after her stem cell transplant.

patients with umbilical cord stem cells and eventu-

Gutman: It wasn’t that they didn’t think of it—the

ity for longer than anyone expected.

ally these stem cells repopulate the blood system,

idea of using donated cord blood to grow more

We’re not just conducting research

C3: Is this stem cell transplant the same

as we’ve seen. But the key there is “eventually.”

cord blood has been around for quite some time.

for the greater good, but for the

as a bone marrow transplant?

In a typical unit of cord blood, there just aren’t

Only, it’s not as easy as it sounds. In the past,

very realistic chance that children

Gutman: Yes and no. In a bone marrow transplant,

enough cells to quickly restart the immune system,

we’ve been able to grow more cord blood, but

can benefit from research going

for a blood cancer like leukemia, you first knock

and in this time between blood systems, patients

not more cord blood stem cells. You treat them to

on today.”

down a patient’s blood system with chemotherapy

are at desperate risk of infection.

grow, but they mature and lose their “stemminess.”

Gore, a CU Cancer Center inves-

This trial uses a brand new technique, growing this

tigator, knew at the age of 12 that

In 1999 the CU medical school

My goal is to help my patients live the life they want to live, for as long as they can.

had recruited a clinical trials expert—colon cancer physician

About Lia Gore, MD

and drug development guru Gail

Director, Experimental Therapeutics Program, Children’s Hospital Colorado

Eckhardt, MD. Gore reached out to Eckhardt, who was building a phase I clinical trials program at University of Colorado Hospital. In August 2001, she started working in the

Associate Professor of Pediatrics and Medicine, University of Colorado School of Medicine Co-Founder and Co-director, Pediatric Experimental Therapeutics Investigators Consortium

C3: Does this new treatment help close the

cord blood in the presence of a special protein that

she wanted to take care of kids with cancer, and

adult phase I clinic with Eckhardt, “because in order

the stem cells in the marrow that regrow a patient’s

window of danger?

makes the umbilical cord stem cells create more

she pursued the dream, landing at Children’s and

to do it well in kids, I needed to learn how to do it

blood system. But in this case we removed the

Gutman: Yes, or at least it seems that way so far.

stem cells, not just more blood. Before this system,

the University of Colorado School of Medicine for

well in adults.”

stem cells from banked umbilical cord blood and

I trained at the Fred Hutchinson Cancer Research

getting a 10- or 20-fold expansion of stem cells

her pediatric residency in 1996 and stayed for

grew them in the lab first before infusing them.

Center, where this stem cell treatment was devel-

was considered a success, and now we’re getting

her pediatric oncology training. In 2001 her post-

100 clinical trials for children and adults. She sits

could, ‘Um … you already have.’ Meaning I had

oped. The Hutch treated 11 patients in Seattle

a 500-fold expansion of these cells.

doctoral research training was over, and she didn’t

on advisory panels to the National Cancer Institute

already cured her cancer. I think about that a lot

know what to do next.

and the executive committee on acute lympho-

because for that one kid, it’s true. Sometimes

blastic leukemia for the Children’s Oncology Group,

I feel completely inadequate because some kids,

Bedrocan /Fli ckr

plant from a matched donor to regrow it. In fact, it’s

and this was our first patient in Colorado, the 12th

In the years since, Gore has directed more than

“I told her, ‘Because I want to cure cancer.’

She looked at me and said, as only a teenager

patient in the world to undergo this procedure. So

C3: That’s how you got the 2.7 billion stem

far, it looks as if growing these stem cells before

cells you infused into your patient?

she recalls. “I had two very good mentors who said,

a national clinical research consortium. She also

I haven’t saved. But my Mom’s story taught me

infusing them makes enough new blood to create

Gutman: Yes, exactly.

‘Let’s think about what’s missing here. You’re not

cofounded the Pediatric Oncology Experimental

that I’m not smart enough to predict the future.

afraid of people who are really sick, and you have

Therapeutics Program, a network of 11 large aca-

We don’t know who can be cured and who can’t.

a good research mind.’”

demic medical centers that promotes development

The fact that there are kids who are alive because

of new, promising therapies for kids, adolescents

of the things we’ve done keeps me coming back

and young adults with cancer.

to work.”

a functioning immune system in less than half the time it takes the standard cord blood transplant.

C3: Where does it go from here?

“I needed a job, and I wanted to stay in Denver,”

Gutman: Well, this procedure is still in a phase

That missing piece: an early clinical trials pro-

C3: Is this an improvement even for people

I clinical trial, but it definitely shows promise. We

gram for kids with cancer. In fact, at the time kids

who can find a matched donor?

hope to see success with more patients. And then,

with the types of cancers most common to the

Gutman: With a matched donor, you have the

in general, we’d like at the CU Cancer Center to

age group—leukemia and brain tumors—were

CU Cancer Center. But working with kids with

program because standard therapy failed. Gore

opposite problem—you can infuse enough bone

use this springboard to develop more of our own

excluded from clinical trials.

cancer is still her first love. Her office at Children’s

says people consider her the “last-ditch doctor.”

marrow stem cells to cut down on the time a

science, our own trials, in addition to continuing to

patient spends without an immune system, but

test promising therapies developed at Fred Hutch

MD, suggested Gore apply for a training grant from

because you need such a high degree of match

and elsewhere. This is an up-and-coming program

the National Institutes of Health called the Paul

between the new blood and the patient’s old blood,

with the potential to become a national leader.

Calabresi Fellowship, a prestigious training program

says. “They may underestimate the impact these

to cure everyone who walks in the door, but

that teaches clinicians how to conduct basic and

kids have on us. Every kid is inspirational because

I also know 7-year-olds who have lived better

translational research. Gore got that training grant,

they keep walking through the door every day,

than 90-year-olds. It’s how you live your life that

and also a mini-fellowship in drug development at

no matter what happens to them.”

really matters.”

the new blood may not recognize traces of the

For an in-depth look at this clinical trial, Dr. Gutman’s work and his patient,

CARE

The Last-Ditch Doctor

On the morning of Aug. 19, 2011, young researcher Jonathan Gutman, MD, and the stem

and radiation, and then use a bone marrow trans-

CLINICAL

LYNN CLARK

a conversation with Jonathan Gutman, MD

One mentor, pediatric oncologist Steve Hunger,

the National Institutes of Health.

She still cares for adult phase I patients at the

is filled with photos and notes from patients and their families reporting in on life.

“Parents are afraid we’ll forget their kids,” she

A patient comes to the phase I clinical trials

“That may be true, but my goal is to help my patients live the life they want to live, for as long as they can,” she says. “Ultimately, I want

She remembers one of her first patients,

see an accompanying article (and video) in the Target: Cancer section

a teenage girl from Highlands Ranch, who asked

of the CU Cancer Center news site, www.coloradocancerblogs.org.

her why she was a doctor.

10

11 www.coloradocancercenter.org

C3: Winter 2011

LYNN CLARK

Nic ole Kofoe d

Don’t call him

Superman B y L y nn C l a r k

Joel Groebner is a living testament to

the power of phase I clinical trials,

faith, and a positive attitude

T

hree times doctors have given Joel Groebner just six months to live. And three times, experimental treatments have stopped the cancer.

Joel has melanoma. The cancer that started as a deep purple mole on the back of his right thigh in 1988 is now in his lungs and liver. Today the disease is stable, thanks to an experimental drug he administers himself.

When he found the mole, surgeons at the Hutchinson, Minn. community hospital removed it and told him that most people—80 percent—with his size of tumor were alive five years later. Three months later, during a yearly physical, doctors found a suspicious lymph node in his right groin. Pathology showed melanoma cells. The cancer had spread.

That was the first time doctors told him to prepare for death.

In terms of outcomes for melanoma, doing nothing and treating with chemotherapy has the same poor result. The best hope for patients with melanoma that has spread beyond the initial tumor site is a clinical trial.

Perhaps doctors underestimated the perseverance and good fortune of the man known to college buddies as “Super J,” because Joel didn’t prepare for death, and 23 years later, he is alive and thriving.

It’s August 2011, and about a dozen doctors, nurses, and clinical trials specialists mingle on the second floor of the Anschutz Cancer Pavilion. As sunlight spills in from the high windows, they laugh and look at the sheet cake, decorated with a cartoon of Superman while they wait for the guest of honor: Joel.

Clinic scheduler Christine Miller coined his Superman nickname.

“We’ve never had a patient like Joel before,” she says. “I don’t know if it’s his faith, or his amazing positive attitude. He’s a supersurvivor, and to us, that makes him Superman.”

A guest, Scott Holden, MD, has come in from California, where he is senior medical director at the pharmaceutical giant Genentech. In 2001, Holden was wrapping up his oncology fellowship in the center’s phase I clinical trials clinic, where he found the drug trial that is holding Joel’s cancer in check.

“Joel is a reminder of what we’re trying to do, and a reminder of what got me into this line of work,” Holden says. “One of the things about phase I clinical trials: You don’t expect things like this—for patients to survive for a decade. There is no way you let something like this go unnoticed.”

Joel arrives with wife Danette and 13-year-old daughter Emerson in tow. He’s tall, with an athletic build. You’d never guess he’s a cancer patient.

With graying red hair and green eyes, he’s the poster child for melanoma risk. Add to his genetics his youth spent as a lifeguard and outdoor tennis champion with nothing but a zinc-oxided nose to protect him—today’s sunscreen did not exist, nor did public awareness of the link between sun exposure and skin cancer—and his risk escalated.

He says he doesn’t blame god for his illness. He laughs and says, “I blame Adam.”

Joel is quick to laugh. At the party, he accepts a piece of cake, hugs his wife, and hugs the individuals who have supported his care over the years. Later, he says he’s not interested in the spotlight.

“The celebration was really for the people who worked with me for 10 years,” he says. “All I had to do was live.”

“Your entire life is taken into consideration when you have this disease,” Joel says. “We decided to say yes to getting pregnant and having a child. My regret is that we missed our window of opportunity to have more children.

In 1997, Joel and a pregnant Danette moved from Minnesota to Longmont, Colo., for Joel’s job as a technology company engineer.

Several months after arriving, he noted something on his abdomen.

An X-ray revealed something in his lung. His family practitioner sent him to Rene Gonzalez, MD, director of cutaneous oncology at the CU Cancer Center and University of Colorado Hospital.

A couple of CTs later, Gonzalez delivered Joel’s second death sentence: The spot on his lung was melanoma.

Joel’s question to Gonzalez: “What are we going to do next?”

The answer: two-and-a-half years on a clinical trial that held his disease at bay but didn’t shrink the tumors, followed by nine months of chemotherapy that had the same effect but made Joel so sick he had to stop. The tumors started growing again. In a last-ditch effort, Joel began biochemotherapy. The treatment is so poisonous that patients are admitted to the hospital rather than getting treatment in an outpatient infusion center.

He endured two complete cycles. His tumors kept growing.

Joel doesn’t remember details about his hospitalization, but does remember his wife’s stalwart support, despite having

“The celebration was really for the people who worked with me for 10 years,” he says.

“All I had to do was live.”

a toddler at home and a full-time job to manage. Danette was by her husband’s side, praying for his recovery. Not every family can survive cancer treatment. The emotional, financial, physical, and relationship stress can be as devastating as the disease.

“Danette’s support is unbelievable,” Joel says, tearing up.

“I can’t imagine doing it alone.”

When biochemo failed in 2001, Joel received his third six-month expiration date. Gonzalez referred him to the center’s early clinical trials program, where he met Holden.

E n t e r PI -8 8 Finding an appropriate clinical trial for people who have failed all standard treatment or other experimental therapies often means “phase I”—or “first in man.” These drug trials are not expected to find something that works, but rather are meant to discover the correct drug dosage and how it works in a human body after it’s been tested in animal models.

Most phase I chemotherapy clinical trials require blood trans­ fusions. Because Joel and his family are Jehovah’s Witnesses, Nicole Kofoed

Su p e r Su rv ivo r

N o stran g e r to c li n i ca l t r ia l s When Joel received his first six-month death sentence in 1988, he and Danette scoured the country for a treatment. They found it at Duke University, where a doctor harvested melanoma cells, irradiated them, then re-injected them to build up immunity.

Joel traveled from Minnesota to Durham seven times in six months for the experimental treatment.

“The doctor said, ‘I probably bought you 10 years,’” Joel recalls. He was right. Joel lived cancer free for almost a decade.

All along, the Groebners struggled with the decision to raise a family in the face of Joel’s cancer diagnosis. Nine years after treatment at Duke, Danette became pregnant with their daughter Emerson.

Joel wanted to live long enough for daughter Emerson to remember him. He has had melanoma for her whole life.

12

13 www.coloradocancercenter.org

C3: Winter 2011

LYNN CLARK

ST RY inside

Sav i n g J o e l G r o e b n e r People who go on phase I cancer clinical trials are pioneers.

They have almost always exhausted all other standard therapies.

And they enroll in the trial with eyes open and no guarantees.

By participating, they help scientists gather information that may help future patients because, unfortunately, most people on phase I clinical trials do not survive as long as Joel. The average life expectancy for someone with metastatic melanoma is months, not years, and certainly not decades.

Ask Joel about the broader purpose for his participation in a clinical trial, and he’ll be blunt. “It’s fantastic that they’ve found something that will work for others, but in the beginning, I was not thinking about the greater good. All I cared about was saving Joel Groebner.”

Julie Banahan, an oncology nurse, has been on Joel’s care team for a decade. “He is the definition of Superman,” she says.

“His attitude is inspiring. He has great karma. You just feel it.”

Lia Gore, MD, who took over Joel’s care when Holden moved on, says, “Joel is defying the odds. He’s at the intersection of science and technology and a few lucky guesses. Who ever thought that he’d live to see his kid go to kindergarten? He’s a vibrant, contributing member to our society.”

Make a donation to support cancer clinical trials at the CU Cancer Center at www.coloradocancerblogs.org/give.

Phase I Clinical Trials put cancer patients on the cutting edge Patients like Joel Groebner (page 12) and Ellen Smith (page 4) are examples of people living at the cutting edge of medical science. Both are taking “experimental” cancer drugs, and the therapies are keeping their diseases in check.

Above: Lia Gore, MD, here with Joel and Scott Holden, says Joel is defying the odds.

Nicole Kofoed

and therefore choose not to take blood transfusions, finding an appropriate trial wasn’t easy.

“We’ve always looked for what new treatments might be available,” Danette says. “We scoured the country for a trial, as did Dr. Holden. Because we didn’t want the blood transfusion, it was disqualified, disqualified, disqualified.”

In August 2001, Holden called and said, “I think I have something for you.” Melanoma tumors are highly reliant on blood vessels to deliver the energy they need to grow and spread. The experimental drug PI-88, manufactured by Progen Pharmaceuticals, inhibits blood vessel formation by targeting a VEGF protein, cutting off its function and therefore starving the tumor.

As Joel started his first treatment week of PI-88, he and Danette understood it was not likely to work, but they believed doing something was better than nothing.

The next month, Joel, Danette and 3-year-old Em traveled to Minnesota for a family reunion. Danette remembers it as awful.

“Everybody knew what was going on—that we were there to say goodbye,” she recalls. “But no one said goodbye.”

Joel remembers it as a beautiful time of year.

“Joel’s always been a glass-half-full guy,” his wife says, laughing.

“His amazing spirit is what has gotten him through this.”

After just two cycles of four bi-weekly PI-88 shots, Joel’s tumors shrunk by half, and then by half again during the next three years.

His disease has been stable since.

Right: PI-88.

Joel says he’s been motivated to fight his disease by the desire to have Em remember him. The couple learned that long-term memory kicks in around age 4 or 5. “We weren’t thinking about 10 years,” Danette says. “We just wanted Em to remember her dad.”

“Now I just want to survive her adolescence,” Joel jokes.

The Groebners say living with Joel’s illness for their entire marriage has taught them, “You can be happy in the most awful circumstances.”

“Your priorities change,” Danette says. “We find ourselves asking, ‘Is this worth arguing over?’ ” Today, Joel is more concerned with developing a secondary cancer from radiation exposure he’s had over the years from CT scans than dying from melanoma. He jokes about worrying about his weight and cholesterol—health concerns the average advanced cancer patient doesn’t have.

He says he is grateful for the experimental drug that Holden found for him, which has allowed Em not only to remember him, but to know him. He’s grateful for the extraordinary team at the CU Cancer Center who have supported him and become his friends. He is grateful for his health insurance, saying, “I must be the $6 million man by now”—referring to the cost of his treatment to date.

Most of all, he is grateful for his wife, and for his daughter, and for his life.

“Some people get cancer and say, ‘I’m done,’” he says. “I don’t get it. If this stops working, I know I have other options. I don’t care what kind of treatment comes next. I have to do something.

I can’t give up. I have too much to live for.”

Cancer clinical trials—the highly regulated and monitored system that tests new drugs, new combinations of drugs and other treatments that are not approved for use by the Food and Drug Administration—are part of standard care at academic cancer centers like the University of Colorado Cancer Center.

Today, nearly every patient at the center’s lead care partners— University of Colorado Hospital and Children’s Hospital Colorado—are evaluated to see if can be offered the option of a clinical trial. Evaluation often includes testing each patient’s tumor to see if the genes, proteins or other biologic factors the experimental drug targets are present. Patients are also evaluated for a host of other factors, including their general health status and the treatments they’ve been on before.

Not all cancer patients are on a phase I clinical trial. In fact, those trials are usually reserved for patients for whom standard treatments have failed. The experimental drug may be their best remaining chance for a response.

F i r st i n M a n New therapies are tested extensively in animal models to see if they work—kill cancer in the way they are designed to—before they are brought to people. Often the drugs are created by pharmaceutical companies, and the companies come to academic cancer centers to “translate” the successful lab discoveries into human patients via a phase I clinical trial.

These so-called first in man trials aren’t looking for whether the drug kills the cancer. Instead, the goal is to determine how it behaves in a human. The clinical trialists—physicians and nurses trained to specifically conduct clinical trials—are looking for dose-limiting toxicities to characterize the body’s general tolerance of the agent. The first group of patients gets the lowest dose, and then the amount of the drug or frequency is increased until patients get intolerable side effects. When that dosage is determined, the drug can move on to phase II testing, where further efficacy testing comes into play.

Sometimes, a small percentage of patients will see their tumors shrink or disappear with an experimental agent. In the past, when trial data was collected on paper and analyzed months after all patients had completed the protocol, these patients were often overlooked. But today, data goes back to the trial sponsors within days or even hours of the patient visit thanks to electronic medical records and databases.

Real-time access to what’s happening in that patient allows doctors to notice trends when they can be taken advantage of.

Time is money, and time is life for these patients.

If a small number of patients respond to the drug, clinical researchers can usually figure out what the commonalities are and open a secondary arm of the trial that enrolls only patients with those features. That’s what happened with crizotinib and patients with the ALK fusion protein in lung cancer, and as a result, the drug is now approved by the FDA for treating those patients just three years after it entered phase I trials.

—Lynn Clark

Can c e r tr ials vs oth e r tr ials All drugs, regardless of disease, have to be extensively and carefully tested before the FDA will approve them for regular use in humans.

But cancer clinical trials are different from the trials you might hear advertised on the radio. Here’s how, using phase I trials as the example.

Phase I Cancer Trial

other Phase I Trial

Only cancer patients can enroll

Normal population can enroll

Patients with limited treatment options

Patients aren’t being treated for a particular disease

Patients do not receive monetary compensation

Patients often receive monetary compensation

Standard care procedures are billed to insurance or the patient

There is no standard care to compare the new drug to

All study treatments and procedures are covered

All costs are covered by the trial

Patients undergo extensive monitoring

Patients undergo extensive monitoring

Goal is to determine correct dosing schedule and toxicity

Goal is to determine levels of toxicity

Also looking at specific characteristics of this patient and this tumor

Not targeted

To search for a cancer clinical trial, visit www.uch.edu/conditions/cancer/research/research_trials/

14 www.coloradocancercenter.org

15 C3: Winter 2011

Screening

p l co

From bookmarks and pocket calendars to newsletters and birthday cards, the participants received six to seven communication pieces per year.

B y Ki m C h r isc a d e n

IMAGES COURTESY OF PLCO

Warriors

PLCO staff share their greatest successes throughout 19 years of research on 13,166 Coloradans

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial has been the Energizer Bunny of cancer trials— going and going and going. After 19 years of research on 13,166 Coloradans, the University of Colorado Cancer Center’s PLCO screening center is closing shop at the end of 2011.

“Conducting a study for 19 years is a long time,” says E. David Crawford, MD, principal investigator of Colorado’s PLCO trial and CU Cancer Center investigator. “We’ve really developed a family and have been able to retain phenomenal employees. I’m certainly going to miss everyone.”

Started in 1992, the PLCO Screening Trial—a National Cancer Institute-funded randomized controlled trial—sought to determine if certain cancer screening tests could reduce prostate, lung, colorectal and ovarian cancer deaths. According to the NCI, these cancers are estimated to account for nearly 40 percent of all diagnosed cancers in the United States and 45 percent of cancer deaths in 2009.

The NCI competitively selected 10 screening centers to recruit 55- to 74-year-old men and women with no PLCO cancer history. Ultimately, the centers recruited nearly 155,000 participants across the country. Patients were randomized into two arms: One that received annual cancer screenings and a second that received information about screenings.

“After all of these years, this study has been a huge learning experience,” says Sheryl Ogden, RN, BSN, PLCO project manager. “When I took this position in 1993, our goal was to get 20,000 people to enroll in the study in Colorado, but none of us had any idea how we were going to recruit that many people.”

Rec ruitment, old -scho ol style In a world of Facebook, Twitter and flash mobs, direct mail may be viewed as an outdated marketing approach, but in the 1990s it was a valuable recruitment tool.

Printed in turquoise and red and with “we need you to make a difference” on the cover, PLCO mailed brochures to tens of thousands of Colorado households from 1993 to 2000, when the last participant was recruited. At the time, obtaining a list of eligible Coloradans was easy.

“Since this was before HIPAA, we were able to ask University of Colorado Hospital for a list of every patient aged 65 to 74 who had never been diagnosed with cancer,” says Ogden. “This gave us enough names for our first mailing, but we needed to find other ways to get names.”

After the first recruitment phase, the NCI added ten years to the trial and allowed 55- to 64-year-olds to participate. This change opened the doors to new names and addresses. PLCO staff hit the jackpot through the Colorado Department of Motor Vehicles with a list of thousands of Coloradans that met trial criteria. Yet enrollment numbers still came up short. The staff resorted to purchasing mailing lists for residents of Colorado Springs, Southern Wyoming, Grand Junction and northern Colorado. In the end, Colorado enrolled 13,166 participants.

Recruiting H ispanics with different tactics In 1998, Colorado’s population was approximately 12.9 percent Hispanic, but PLCO enrollment was only 3.9 percent. To recruit more minorities, the NCI decided to grant additional funding to PLCO sites interested in recruiting Hispanics and African Americans. Colorado launched a 16-month Hispanic recruitment campaign, “Por Nosotros y Nuestros Hijos,” which translates to “For Ourselves and Our Children,” with input from Hispanic community members.

Direct mail did not work with this population, says Sally Tenorio, RN, BSN, PLCO Hispanic retention coordinator.

Through speaking at churches, recruitment seminars and oneon-one community health clinic visits, the PLCO team recruited 1,062 Hispanic participants—more than any other study site.

PLCO at a glance 155,000+ US participants 13,116 Colorado participants 19 years of data collection 2.7 million biologic samples collected with related outcomes information

See a slideshow of more PLCO cards on our blog.

F i rst S cientifically V e r ified L un g C ance r S c r eenin g T est

“We really had to connect with people at the community level in churches and clinics and explain the study to them,” she says. “[Recruitment] took more face time. The Hispanic community was very interested in how the outcomes of the study could be used to educate their family and children about their health.

Participants brought their entire families to the screenings so that they could also be informed and educated.”

H um or, c reativity aided retenti on With 13,166 participants, PLCO staff were challenged to keep everyone engaged with the study over the long haul.

From bookmarks and pocket calendars to newsletters and birthday cards, the participants received six to seven communication pieces per year. At first, Colorado PLCO staff sent traditional cards to each participant, but then they decided to get creative.

The card covers evolved into funny photos of PLCO staff riding go-carts, wearing western attire and hitting piñatas. At the end of the trial, a satisfaction survey revealed how much participants enjoyed the birthday and holiday cards, Ogden says.

“We wanted participants to know the staff they were talking to on the phone and getting mail from,” Ogden says. “They really enjoyed those cards and often wanted to know where they could get more pocket calendars.”

The Colorado PLCO site became known for its high retention rates, and many of their techniques were put into practice across the country. About 90 percent of the people recruited were still engaged at the end of the Colorado study, and about 67 percent will continue participating as the trial moves to a central administration in 2012.

Because PLCO screening sites had experience with enormous randomized population trials, the The NCI asked the sites to take on a new study in 2002. The National Lung Screening Trial compared lung cancer screening with low-dose helical computed tomography, or CT, and standard chest X-ray.

From 2002 to 2004, more than 53,000 current or former heavy smokers aged 55 to 74 enrolled in NLST, including 3,743 Coloradans. In 2011, NLST published ground-breaking results: Participants screened by low-dose helical CT scans had a 20 percent lower risk of dying from lung cancer than participants screened by standard chest X-rays. It is the first scientifically verified lung cancer screening test, and its impact will be felt for generations.

Though PLCO screening results published so far haven’t shown a reduction in prostate or ovarian cancer mortality from screening—results for lung and colon screenings are yet unpublished—the study collected significant amounts of data and biologic samples about people who have and have not gone on to get cancer. Approximately 2.7 million biologic specimens, including blood and cell samples, are available to researchers for studies on a vast array of health questions.

“The study will impact future research for years to come,” Ogden says.

The end , but n o t the end Participants who agreed to continue in the study will be transferred to a central center and followed for an additional five years. PLCO screening results will be updated and published in coming years.

As the study comes to a close, Crawford says, the PLCO will be remembered as the study that “brought a lot of patients to the [University of Colorado Hospital], raised awareness of the CU Cancer Center and School of Medicine, and contributed significant research dollars to this campus.”

By December, dust will disappear from office shelves, archives will be shipped across the country, and goodbyes between co-workers and friends will be endless. Although the PLCO trial couldn’t outlive the Energizer Bunny, its results—and massive data set—will benefit cancer patients long into the future.

16

17 www.coloradocancercenter.org

C3: Winter 2011

S U P P O R T E R

F CUS

Putting Stake in Untested Research RONALD WH ITE

Gary R e e c e , P r e s i d e n t Ca n c e r l e agu e o f C o lo r a d o b y k i m c h r isc a d e n

C O M M U N I T Y

N E W S

Save the Date: March 8 Cocktails for a Cure Join AMC Cancer Fund on March 8, 2012, for an evening of cocktails and hors d’oeuvres celebrating Colorado women and supporting

RONALD WH ITE

Gary Reece is no stranger to philanthropy. Barbara, his wife of 37 years, spent her career as a professional philanthropist for many Denver nonprofits.

the continued research and treatment of women’s cancers at the CU Cancer Center.

Featuring guest bartenders from some of

His former boss also donated to multiple causes

Denver’s top establishments, Cocktails for

and encouraged his employees to do the same.

a Cure is an opportunity for women to have

While Gary got behind his wife’s causes,

a girls’ night out while participating in a silent

attending multiple local benefits and galas, he didn’t

Golfers Against Cancer, AMC Cancer Fund donate $200,000 for pilot projects

auction and sipping on signature drinks.

directly involve himself in the fundraising until 2008.

Golfers Against Cancer and AMC Cancer Fund

“One of the first projects we funded—a gastro-

Stacy Carpenter, Keri Christiansen, Evalinda

have awarded $200,000 in seed grants to four

intestinal cancer tumor bank focused on colorectal

Urman and Libby Weaver. Tickets are $150

groups of CU Cancer Center investigators.

and pancreas cancer—has received a $1 million

and include heavy hors d’oeuvres, signature

The grants will be used to investigate new

grant from the National Institutes of Health,” says

cocktails, wine and beer. Purchase tickets at

cancer solutions.

Scott Pearson, Golfers Against Cancer’s president.

www.amc.org/events.

“We know that collaboration is essential to the advancement of cancer research and supporting these grants is our opportunity to be a part of it.”

—alice norton, amc cancer fund ceo

This year’s honorary chairs include Sue Allon,

That year, after 20 years of service as a financial executive at M.D.C. Holdings, Inc., Gary retired and quickly found his cause—cancer research.

“I guess you can say I’ve learned from the best when it comes to getting behind great causes,” Gary says.

Since cancer has claimed the lives of several members of the Reece family, including Gary’s

Left: Gary and Barbara Reece trade in the golf course for a more fulfilling retirement plan.

father and Barb’s grandmother, it was natural for the couple to join Cancer League of Colorado,

Above: Gary rappels down a Denver skyscraper at the Cancer League ‘Over The Edge’ fundraiser.

money to support cancer research in Colorado.

“Cancer League of Colorado is made up of

In September 2011, Cancer League made

totaling more than $10 million in grants to the Cancer Center since 1985.

people who have been touched by cancer and

its largest pledge to the CU Cancer Center when

want to do something to keep the ones they love

it announced it would commit $2 million toward

alive,” Gary says.

an endowed chair, a step further in advancing

Cancer League has played a key early-stage role

By funding innovative cancer research projects,

world-class cancer research here in Colorado,

in treatments and tests that directly benefit cancer

already serving as president of the organization.

says Dan Theodorescu, MD, PhD, center director

patients around the world, including sputum testing

Naturally, Gary found himself assuming a leadership

and professor of surgery and pharmacology at

that aids noninvasive diagnosis of lung cancers.

role; and in 2009 he was elected to take over as

the CU School of Medicine.

At the time of Gary’s retirement, Barbara was

president. He is serving his second term.

“Cancer League of Colorado has helped the

Many of these grants, which are selected by a scientific advisory committee that includes Cancer

Cancer Center fund innovative science in the

Center members and other researchers, wind up

about what they do,” says Gary. “It’s most reward-

pursuit of our goal of relieving suffering from

generating $20 in federal research funding for every

ing when we’re able to pull the dollars together to

cancer,” Theodorescu says. “We may use this

dollar they grant to a researcher in seed funding.

fund projects that make a difference and eventually

chair to recruit an eminent cancer scientist who

gain the attention and additional funding from the

will lead and pursue innovative cancer research

Colorado know that we are here to help fund their

National Institutes of Health.”

in areas of strategic importance to our center.”

research projects and we hope to continue to grow

“I enjoy working with people who are passionate

Filling a unique niche, Cancer League provides

In discussions with Cancer Center leaders,

seed grants for promising yet untested cancer

Gary asked, “How can we have the greatest

research projects—the types of grants no other

impact in the fight against cancer in the state

funder offers on a systematic basis in the Rocky

of Colorado?”

Mountain region.

“It became very clear that, to be one of the

“We want to make sure all researchers in

seeking an additional $5 million grant. These are

stepped in with an additional $9,000 to fund both

great examples of how a little donation can go

projects at $50,000 each. The group’s board

a long way.”

Dara Aisner, MD, PhD: Feasibility Study

AMC Cancer Fund, one of CU Cancer Center’s fundraising partners, also stepped in to fund two additional projects at $50,000 each:

for Large-scale, Population-based Validation

Behind the Curtain raises $115,000 for

of a Molecular Staging

the Anschutz Cancer Pavilion Behind the Curtain, a women’s-only event about

David Barton, PhD and Jay Hesselberth,

prostate cancer, raised $115,000 for the expan-

PhD: Hepatitis C Virus Infections, Inflammation

sion of the Anschutz Cancer Pavilion at the

and Liver Cancer

Mair Churchill, PhD and Heide Ford, PhD: Pharmacologically Targeting Histone Chaperones for Breast Cancer Treatment Michael Graner, PhD, Natalie Serkova, PhD and Allen Waziri, MD: Metabolomics

University of Colorado Hospital. Entertainment

of Glioblastomas and Tumor Tissues in a Novel

was provided by the creators of “Girls Only.”

While Gary may have planned to spend his

Since 2009, Golfers Against Cancer has given more

Organotype Tumor Slice Culture Model—

than $200,000, which has resulted in an additional

Stress Responses and the Dynamic Tumor

$2 million in grants or matching funds.

Metabolome

Cancer League of Colorado commits $2 million toward endowed chair Cancer League of Colorado has filled a unique niche for 43 years, providing seed grants for promising yet

time meeting with cancer researchers, managing

untested cancer research projects to scores of CU Cancer Center researchers.

researchers have earned these grants and parlayed

best doctors,” he says. “Some of these doctors

ing his family further their careers and devotions.

them into far larger grants from federal funders

cannot be recruited without the benefit of an

such as the National Institutes of Health when these

endowed chair.”

In September, Cancer League announced a $2 million pledge toward a Cancer League of Colorado endowed

“If being a part of the Cancer League wasn’t fun

chair at the CU Cancer Center, a step further in advancing

and I wasn’t enjoying it, I wouldn’t be a part of it,”

Dinner in White raises the bar and $20,000

world-class cancer research here in Colorado, says center

he says.

Modeled after the Diner en Blanc in Paris,

director Dan Theodorescu, MD, PhD.

its funding with an endowed chair. In July, it

the 2nd annual Dinner in White, hosted by the

distributed an additional $600,000 in seed grants to 18 CU Cancer Center investigators,

already received an additional $660,000 and is

for the CU Cancer Center. An anonymous donor

retirement on the golf course, he now spends his Cancer League’s day-to-day operations, and help-

lines of inquiry.

auction, Golfers Against Cancer raised $91,000

Heather Feigelson, PhD and

great projects in Colorado,” Gary says.

best cancer centers in the country, we need the

This year, Cancer League didn’t stop

“The project for acute myeloid leukemia has

selected two projects to fund:

our research grant program to fund even more

Scores of University of Colorado Cancer Center

early research investigations proved to be fruitful

Through an annual summer golf tournament and

STEVE Z PHOTOGRA PHY

an all-volunteer nonprofit organization that raises

AMC Cancer Fund, raised $20,000 for cancer Learn more about Cancer League of Colorado at www.cancerleague.org.

research at the CU Cancer Center.

Read about Cancer League’s president, Gary Reece, on page 18.

18

19 www.coloradocancercenter.org

C3: Winter 2011

University of Colorado Denver

W I N T E R 2 011

13001 East 17th Place, MSF434 Aurora, CO 80045-0511

www.coloradocancercenter.org

RETUR N S ER V I C E RE Q UE S TED

C3: Collaborating to Conquer Cancer Published twice a year by University of Colorado Denver for friends, members and the community of the University of Colorado Cancer Center.

(No research money has been used for this publication.)

Editor: Lynn G. Clark | 303-724-3160 | Lynn.Clark@ucdenver.edu Contributing Writers: Kim Chriscaden, Garth Sundem Photos: Lynn Clark, Glenn Asakawa, Nicole Kofoed, Ronald White Design: EnZed Design The CU Cancer Center Consortium Members Universities

Colorado State University University of Colorado Boulder University of Colorado Denver Institutions

University of Colorado Hospital Children’s Hospital Colorado National Jewish Health Denver Health Medical Center Denver Veterans Affairs Medical Center Kaiser Permanente Colorado Visit us on the web: www.coloradocancercenter.org The CU Cancer Center is dedicated to equal opportunity and access in all aspects of employment and patient care.

T H E

M E S S A G E

40 years after the war on cancer began, I feel more hopeful than ever for my patients

A

s a cancer surgeon, I know how critical it is to remove

and understand the planets in Orion’s belt. Concepts that were

every last bit of cancer from my patient’s body. The more

once just specs of light in a far mysterious distance are now real,

that is left behind, the more likely it is that the cancer will

understandable and world-changing.

return. As a cancer biologist, I also know how critical it is to know

I believe we are in a perfect storm of technology, knowledge

exactly what errant genes or proteins are causing the tumors to

and communication. As you’ll read in this issue of Collaborating

grow and spread so they can be targeted with drugs that stop

to Conquer Cancer, in Colorado we are making specific and

those errant actions.

giant leaps forward through discoveries that only come from this

I also know that there is a fine balance between too much

storm, and from leveraging the enormous pool of talent, experi-

healthy tissue removed, or too many healthy cells dying, in the race to cure the patient.

We often throw around the term person-

FROM THE DIRECTOR Dan Theodorescu, MD, PhD

alized medicine, and yet we assume that everyone knows what we’re talking about.

The obvious definition in cancer is finding the treatment that takes advantage of an individual patient’s tumor characteristics, including the genes and proteins, the tumor environment and other mechanisms at play, to kill the cancer. Integral to this success also requires a fundamental understanding of the host—

ence and knowledge assembled in our 442 cancer

“We now have fine-tuned knowledge and technology that allows us to be more precise, to do less harm in saving a patient’s life.”

the normal organism that harbors the cancer. This knowledge is important in such aspects as harnessing the immune system to kill

center members across the state. Our cancer center represents the majority of the state’s effort in cancer research.

Standing behind them: our generous donors, such as Cancer League of Colorado, whose volunteer-driven organization has provided millions of dollars in funding for start-up science projects, and which has just committed to raising $2 million for a new endowed chair in cancer research that will help us recruit an outstanding cancer researcher. Also standing behind them are the remarkable patients

and families who are on this journey with them.

Today, we are becoming more precise in our understanding

the cancer as well as understanding how anticancer drugs may be

of the seemingly never-ending mechanisms of cancer as hun-

metabolized (broken down) by the patient.

dreds of individual diseases. We are becoming more precise in

Forty years ago when the National Cancer Institute was

how we use that knowledge to personalize treatment for every

formed, cancer treatment was in an era of cut it all out, give the

patient. And we are becoming more precise in how we test for

highest doses of chemotherapies possible or almost killing the

disease in the first place.

patient to save the patient. Four decades later, we now have

Forty years after cancer became a war, I feel more hope than

fine-tuned knowledge and technology that allows us to be more

ever for my patients and for cancer patients all around the world

precise, to do less harm in saving a patient’s life. If we could

that we will prevail in this fight in our lifetimes.

see and understand the moon back in 1971, today we can see

20 www.coloradocancercenter.org